Jun 10, 2024, 07:25
The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 – Yale Cancer Center
Yale Cancer Center shared a post on X:
“The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 showed Lu-Dotatate should be considered a new standard of care in 1st line therapy for pts with grade 2 or 3 advanced gastroenteropancreatic neuroendocrinetumors.”
Additional information.
Source: Yale Cancer Center/X